Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological, neuropsychiatric, immunological, and rare diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 49 | New buy | 20,060 | $301,101 | 0.0% |
| Paul Tudor Jones / Tudor | 57 | Trimmed -13% | 126,291 | $1,895,628 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-03-09 | CHILDS JOHN W | director | 28,400 | $864,212 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.